



PHYSICIAN ASSISTANT POLICY COMMITTEE MINUTES

August 8, 2017

The meeting was called to order at approximately 1:34 p.m. on Tuesday August 8, 2017.

Committee members present: Donald Roberts, Robert Zaayer, PA-C; Scott Cackler, PA-C; Curtis Gingrich, M.D., Joshua Cox, R.Ph.; and Anita Steinbergh, D.O.

Staff members present: Sallie Debolt, and Cathy Hacker.

Guest: Mandi Grandjean, OAPA, Beth Adamson, OAPA, Greg Lestini, OAPA.

I. Review of the July 11, 2017 minutes:

Dr. Steinbergh moved to approve the minutes. Mr. Cackler seconded the motion. All other members voted aye. The motion carried.

Ms. Debolt stated that there was an omission in the March 2016 minutes. It was requested that the March 2016 PAPC minutes be amended to reflect that the committee reviewed rule 4731-21 and recommended it for filing at CSI.

II. Formulary Review

The committee recommended that PA's be able to order Buprenorphine for administration in a hospital setting without the data waiver for use other than for opioid dependency.

Dr. Steinbergh moved to approve this change. Mr. Cackler seconded the motion. All members voted aye. The motion carried.

The committee discussed where Zinplava was placed in the formulary under the miscellaneous GI agents. Mr. Zaayer and Dr. Gingrich both agreed that the listing of this medication under the miscellaneous GI agents indicates its accepted use and does not limit PA usage to those within a GI specialty. Therefore there is no need to alter the current formulary. No change was made to the formulary.

It was brought to the committee's attention that Taltz was on the formulary but not Cosentyx. Mr. Cox noted that this is a Biological response modifier and but one example of this class of medication. He recommended to add anti psoriatic monoclonal antibodies category and that this would cover all psoriatic medications.

Dr. Steinbergh moved to add the category anti psoriatic monoclonal antibodies to the formulary in the physician initiated category. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

The committee then reviewed the request from Cleveland Clinic requesting that Immune-Suppressants; Immune-modulators; Interferon; Monoclonal antibodies; and potassium channel blockers all be moved to the CTP holder may prescribe category from the CTP may not and the PI category. Dr. Steinbergh wants them all to be PI by protocol in a hospital setting. Mr. Cackler agreed, however, he stated that some of these medications can be used

for other purposes and should be in the PI category. Mr. Cox noted that Xgeva was in the wrong category on the formulary.

Dr. Steinbergh moved to put all of these medications in the PI/Consult category and to add that in a neurologist practice only. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

The request by Caitlin Jones for clarification for the use of HCG while practicing in a physical medicine practice was reviewed. The rationale for utilization of this medication after review of its approved indications was not clear.

Dr. Steinbergh moved to table this request and ask for clarification of what the HCG hormone would be used for. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

III. New business

Dr. Gingrich stated that a Survey Monkey was sent to all members of the committee and that only 3 responses were received. Mr. Cackler stated that he did not receive the survey. Dr. Gingrich proposed that the PAPC meetings be moved to the 1st Monday of every month starting at 8:30A.M.-10:00 A.M. Mr. Cox stated that he was unable to commit to that date due to his work obligations. Mr. Cox offered to work with Ms. Keller to be certain that at least one of the Pharmacists would be available for each meeting. Mr. Cox felt that the 2nd Monday of the month would be a better time for him so long as he would be able to also attend the Pharmacy Board meeting by 10 a.m.

Dr. Gingrich moved to change the PAPC meeting dates to the 2nd Monday of the Month to start at 8:30 a.m. and to last no later than 10:00 a.m. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

Mr. Lestini informed the committee that the OAPA wants to legislatively change the formulary to use FDA approved drugs as the list of drugs for PA's to prescribe instead of the current formulary. Potential short term solutions to allow all new medication be added to the formulary and then reviewed by the committee for recommendations was discussed. It was determined that this would not be in the best interest of public safety and could add confusion to the prescribing ability of PA's if the default was to allow a medication and then it was subsequently removed. The committee will continue to monitor and work to improve its efficiency at reviewing medication requests and new medications and voiced understanding of the goal of Mr Lestini to seek legislative change during the current legislative cycle.

The Physician Assistant Policy Committee meeting was adjourned by Dr. Gingrich at approximately 3:00 p.m. on Tuesday, August 8, 2017.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on August 8, 2017.

Curtis Gingrich, MD, Chair, PAPC